Charnwood Molecular, a UK-based preclinical discovery CRO servicing the global pharmaceutical and biopharma market, is planning a significant expansion in 2021.   Charnwood Molecular will continue to build on its medicinal chemistry, scale-up chemistry and custom synthesis provision, evolving its business strategy to deliver increasingly high-tech and high-value research capabilities. To enable the expansion, Charnwood Molecular recently partnered with Synova, a leading European private equity...